“…This between-attack patient burden can reflect anxiety in anticipation of the next painful attack and concern over the potential impact on future plans and activities [24]. There may also be reduced quality of life between attacks related to more general feelings of anxiety, depression, irritability, and sleepiness, which have been observed with greater frequency among migraineurs than corresponding population controls [24][25][26][27] However, the degree to which one or more of these health effects are the result of migraine itself, side effects of medication use (e.g., sleepiness), or independent conditions resulting from some shared risk factor for migraine is not fully understood. Randomized, double-blind, placebo-controlled clinical trials of prophylactic migraine treatments exhibiting efficacy in reducing headache days have produce mixed results, with several studies showing a statistically significant benefit on some quality of life indices [28][29][30][31][32] and others failing to do so [33,34].…”